Azurity Pharmaceuticals, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$979Kgeneral payments (2019-2025)
$3,975research payments (2019-2025)
16,642clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Horizant $287K associated (2023-2025)
- Edarbi $96K associated (2023-2025)
- Triptodur $74K associated (2023-2025)
- Zonisade $51K associated (2023-2025)
- Widaplik $48K associated (2023-2025)
- Danziten $42K associated (2023-2025)
- Alvesco $39K associated (2023-2025)
- Azmiro $30K associated (2023-2025)
- Edarbyclor $29K associated (2023-2025)
- Adthyza $22K associated (2023-2025)
- Vivimusta $20K associated (2023-2025)
- Eprontia $6,222 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| John Winkelman | Boston, MA | Sleep Medicine (Psychiatry & Neurology) | $34,857.47 |
| John Mahan | Columbus, OH | Pediatric Nephrology | $17,250.00 |
| Scott Weir | Falls Church, VA | Emergency Medicine | $17,062.50 |
| Joshua Yang | Orlando, FL | Pediatric Endocrinology | $16,872.69 |
| James Wheless | Memphis, TN | Neurology With Special Qualifications In Child Neurology | $15,336.55 |
| Patricia Dean | Miami, FL | Pediatrics (Nurse Practitioner) | $12,387.90 |
| William Cushman | Memphis, TN | Internal Medicine | $11,523.76 |
| Siham Accacha | Mineola, NY | Pediatric Endocrinology | $11,068.78 |
| Jerome Lane | Chicago, IL | Pediatric Nephrology | $8,755.00 |
| Robert Reder | Woburn, MA | $8,628.50 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.